Cardiogenic Shock

Part of the Contemporary Cardiology book series (CONCARD)


Shock is a clinical state in which target tissue perfusion is inadequate to supply vital substrates and remove metabolic waste. Inadequate cellular oxygenation leads to marked generalized impairment of cellular function and multiorgan failure. Autopsy studies indicate that combined new and old extensive myocardial infarctions (MIs) consistently involve more than 40% of the left ventricular (LV) myocardium.


Right Ventricular Cardiogenic Shock Pulmonary Capillary Wedge Pressure Left Ventricular Filling Pressure Severe Mitral Regurgitation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Califf RM, Bengston JR. Current concepts: cardiogenic shock. N Engl J Med 1994;24:1724.CrossRefGoogle Scholar
  2. 2.
    Cotter G, Kaluski E, Milo O, et al. LINCS: l-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003;24:1287–1295.PubMedCrossRefGoogle Scholar
  3. 3.
    Dargie HJ. Effect of carvediol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–1390.PubMedCrossRefGoogle Scholar
  4. 4.
    Eltchaninoff H, Simpfendorfer C, Whitlow PL. Coronary angioplasty improves early and 1 year survival in acute myocardial infarction complicated by cardiogenic shock. J Am Coll Cardiol 1991;17:167A.CrossRefGoogle Scholar
  5. 5.
    Ghitis A, Flaker GC, Meinhardt S, et al. Early angioplasty in patients with acute myocardial infarction complicated by hypotension. Am Heart J 1991;122:380.PubMedCrossRefGoogle Scholar
  6. 6.
    Grines CL, Growne KF, Marco J, et al. For the primary angioplasty in myocardial infarction study group: a comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673.PubMedCrossRefGoogle Scholar
  7. 7.
    Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107:2998–3002.PubMedCrossRefGoogle Scholar
  8. 8.
    Hochman J, Sleeper L, Webb J, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625–634.PubMedCrossRefGoogle Scholar
  9. 9.
    Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190–192.PubMedCrossRefGoogle Scholar
  10. 10.
    Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: overall findings of the SHOCK Trial Registry. J Am Coll Cardiol 2000;36:1063–1070.PubMedCrossRefGoogle Scholar
  11. 11.
    Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000;190:244–254.PubMedCrossRefGoogle Scholar
  12. 12.
    Webb JG, Sanborn TA, Sleeper L, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001;141:964–970.PubMedCrossRefGoogle Scholar
  13. 13.
    Wildhirt SM, Dudek RR, Suzuki H, et al. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol 1995;50:253–261.PubMedCrossRefGoogle Scholar
  14. 14.
    Wollert KC, Drexler H. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the β-blocker world? Circulation 2002;106:2164–2166.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations